Chinese and Western medicine treatment for lower urinary tract dysfunctions in postmenopausal women: a systematic review

doi:10.3969/j.issn.1006-7795.2024.05.020

Abstract

Abstract: Lower urinary tract dysfunction (LUTD) is a key problem for patients with genitourinary syndrome of menopause (GSM). LUTD is mainly caused by low estrogen levels, urogenital atrophy, urinary tract infections and alterations in the vaginal microbiota. These symptoms adversely affect many aspects of a woman's daily life. LUTD treatment involves traditional Chinese and Western medicine prevention and health monitoring. Vaginal low estrogen in the treatment of LUTD is the mainstay of medical treatment which is a key comprehensive, individualized and synergistic therapeutic approach to restore urogenital physiology. This review describes the research progress of menopause and Chinese and Western medicine treatment for LUTD.

Key words: menopause, genitourinary syndrome of menopause, lower urinary tract dysfunctions, hormone treatment, electroacupuncture

CLC Number:

Zhao Yue, Zhang Quandong. Chinese and Western medicine treatment for lower urinary tract dysfunctions in postmenopausal women: a systematic review[J]. Journal of Capital Medical University, 2024, 45(5): 875-880.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2024.05.020

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2024/V45/I5/875

References

［1］Jahangirifar M, Fooladi E, Davis S R, et al. Menopause symptoms, sexual dysfunctions and pelvic floor disorders in refugee and asylum seeker women: a scoping review［J］. Climacteric, 2023, 26(4): 373－380.
［2］Peinado-Molina R A, Hernández-Martínez A, Martínez-Vázquez S, et al. Pelvic floor dysfunction: prevalence and associated factors［J］. BMC Public Health, 2023, 23(1): 2005.
［3］Filippini M, Biordi N, Curcio A, et al. A qualitative and quantitative study to evaluate the effectiveness and safety of magnetic stimulation in women with urinary incontinence symptoms and pelvic floor disorders［J］. Medicina, 2023, 59(5): 879.
［4］Mori da Cunha M G M C, Mackova K, Hympanova L H, et al. Animal models for pelvic organ prolapse: systematic review［J］. Int Urogynecol J, 2021, 32(6): 1331－1344.
［5］Sammarco A G, Sheyn D D, Krantz T E, et al. A novel measurement of pelvic floor cross-sectional area in older and younger women with and without prolapse［J］. Am J Obstet Gynecol, 2019, 221(5): 521.e1－521.e7.
［6］Crandall C J, Mehta J M, Manson J E. Management of menopausal symptoms: a review［J］. JAMA, 2023, 329(5): 405－420.
［7］Valadares A, Kulak J J, Paiva L, et al. Genitourinary syndrome of menopause［J］. Rev Bras Ginecol Obstet, 2022, 44(3): 319－324.
［8］van Geelen H, Sand P K. The female urethra: urethral function throughout a woman's lifetime［J］. Int Urogynecol J, 2023, 34(6): 1175－1186.
［9］Clark A L, Goetsch M F. Genitourinary syndrome of menopause: pathophysiology, clinical presentation, and differential diagnosis［J］. Clin Obstet Gynecol, 2024, 67(1): 13－26.
［10］Bodner-Adler B, Alarab M, Ruiz-Zapata A M, et al. Effectiveness of hormones in postmenopausal pelvic floor dysfunction-International Urogynecological Association research and development-committee opinion［J］. Int Urogynecol J, 2020, 31(8): 1577－1582.
［11］Dietz H P, Socha M, Atan I K, et al. Does estrogen deprivation affect pelvic floor muscle contractility?［J］. Int Urogynecol J, 2020, 31(1): 191－196.
［12］Sipos A G, Kozma B, Poka R, et al. The effect of fractional CO2 laser treatment on the symptoms of pelvic floor dysfunctions: pelvic floor distress inventory-20 questionnaire［J］. Lasers Surg Med, 2019, 51(10): 882－886.
［13］Carter A E, Merriam S. Menopause［J］. Med Clin North Am, 2023, 107(2): 199－212.
［14］Sarmento A C A, Costa A P F, Vieira-Baptista P, et al. Genitourinary syndrome of menopause: epidemiology, physiopathology, clinical manifestation and diagnostic［J］. Front Reprod Health, 2021, 3: 779398.
［15］Tomoe H, Ozaki Y, Yamamoto M, et al. Epidemiological study of genitourinary syndrome of menopause in Japan (GENJA study)［J］. Menopause, 2023, 30(4): 447－453.
［16］La Rosa V L, Ciebiera M, Lin L T, et al. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function［J］. Prz Menopauzalny, 2019, 18(2): 116－122.
［17］Christmas M M, Iyer S, Daisy C, et al. Menopause hormone therapy and urinary symptoms: a systematic review［J］. Menopause, 2023, 30(6): 672－685.
［18］Bapir R, Bhatti K H, Eliwa A, et al. Treatment of urge incontinence in postmenopausal women: a systematic review［J］. Arch Ital Urol Androl, 2023, 95(3): 11718.
［19］Jang Y C, Leung C Y, Huang H L. Comparison of severity of genitourinary syndrome of menopause symptoms after carbon dioxide laser vs vaginal estrogen therapy: a systematic review and meta-analysis［J］. JAMA Netw Open, 2022, 5(9): e2232563.
［20］Trémollieres F, Chabbert-Buffet N, Plu-Bureau G, et al. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines (short version)［J］. Gynecol Obstet Fertil Senol, 2021, 49(5): 305－317.
［21］Cox S, Nasseri R, Rubin R S, et al. Genitourinary syndrome of menopause［J］. Med Clin North Am, 2023, 107(2): 357－369.
［22］Pitsouni E, Grigoriadis T, Falagas M E, et al. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis［J］. Maturitas, 2017, 103: 78－88.
［23］Nemirovsky A, Villela N A, Yuan J C, et al. Vaginal hormone therapy for conditions of the lower urinary tract［J］. Curr Urol Rep, 2023, 24(2): 41－50.
［24］Bhattacharya S, Singal A K, Kalra S. The endocrinology of the urinary bladder［J］. J Pak Med Assoc, 2023, 73(12): 2488－2490.
［25］Benini V, Ruffolo A F, Casiraghi A, et al. New innovations for the treatment of vulvovaginal atrophy: an up-to-date review［J］. Medicina, 2022, 58(6): 770.
［26］Park M G, Cho S, Oh M M. Menopausal changes in the microbiome-a review focused on the genitourinary microbiome［J］. Diagnostics, 2023, 13(6): 1193.
［27］Pérez-López F R, Fernández-Alonso A M, Mezones-Holguín E, et al. Low genitourinary tract risks in women living with the human immunodeficiency virus［J］. Climacteric, 2023, 26(4): 316－322.
［28］Rahn D D, Richter H E, Sung V W, et al. Effects of preoperative intravaginal estrogen on pelvic floor disorder symptoms in postmenopausal women with pelvic organ prolapse［J］. Am J Obstet Gynecol, 2023, 229(3): 309.e1－309.e10.
［29］Andreeva E N, Sheremetyeva E V. The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women［J］. Probl Endokrinol, 2022, 68(6): 157－163.
［30］Patil A. Response to “a comparative study of alpha-1a blockers (tamsulosin) versus estrogens in the treatment of lower urinary tract symptoms in perimenopausal females”［J］. Indian J Pharmacol, 2020, 52(6): 524－525.
［31］Ligon M M, Joshi C S, Fashemi B E, et al. Effects of aging on urinary tract epithelial homeostasis and immunity［J］. Dev Biol, 2023, 493: 29－39.
［32］Hardy C C, Korstanje R. Aging and urinary control: alterations in the brain-bladder axis［J］. Aging Cell, 2023, 22(12): e13990.
［33］Wasnik V B, Acharya N, Mohammad S. Genitourinary syndrome of menopause: a narrative review focusing on its effects on the sexual health and quality of life of women［J］. Cureus, 2023, 15(11): e48143.
［34］Wu C, Newman D, Schwartz T A, et al. Effects of unsupervised behavioral and pelvic floor muscle training programs on nocturia, urinary urgency, and urinary frequency in postmenopausal women: secondary analysis of a randomized, two-arm, parallel design, superiority trial (TULIP study)［J］. Maturitas, 2021, 146: 42－48.
［35］ElSheikh M A, Atia A A, Metwaly N S, et al. Influence of self-care guidelines on improving menopausal urogenital symptoms［J］. J Pak Med Assoc, 2023, 73(suppl 4)(4): S210-S214.
［36］Biscola N P, Bartmeyer P M, Christe K L, et al. Detrusor underactivity is associated with metabolic syndrome in aged primates［J］. Sci Rep, 2023, 13(1): 6716.
［37］Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review［J］. Ann Clin Microbiol Antimicrob, 2020, 19(1): 5.
［38］Alvisi S, Ceccarani C, Foschi C, et al. Effect of ospemifene on vaginal microbiome in postmenopausal women with vulvovaginal atrophy［J］. Menopause, 2023, 30(4): 361－369.
［39］Stabile G, Topouzova G A, De S F. The role of microbiota in the management of genitourinary syndrome of menopause［J］. Climacteric, 2023, 26(4): 353－360.
［40］Yoshikata R M, Yamaguchi M, Mase Y R, et al. Age-related changes, influencing factors, and crosstalk between vaginal and gut microbiota: a cross-sectional comparative study of pre- and postmenopausal women［J］. J Womens Health, 2022, 31(12): 1763－1772.
［41］Lumsden M A, Davies M, Sarri G. Diagnosis and management of menopause: the national institute of health and care excellence (NICE) guideline［J］. JAMA Intern Med，2016，176(8):1205-1206.
［42］Van Gerwen O T, Smith S E, Muzny C A. Bacterial vaginosis in postmenopausal women［J］. Curr Infect Dis Rep, 2023, 25(1): 7－15.
［43］Chen Q, Wang H J, Wang G, et al. Lactic acid bacteria: a promising tool for menopausal health management in women［J］. Nutrients, 2022, 14(21): 4466.
［44］Dothard M I, Allard S M, Gilbert J A. The effects of hormone replacement therapy on the microbiomes of postmenopausal women［J］. Climacteric, 2023, 26(3): 182－192.
［45］Musbahi E, Kamp E, Ashraf M, et al. Menopause,skin and common dermatosis. Part 3: genital disorders［J］. Clin Exp Dermatol, 2022, 47(12): 2123－2129.
［46］Waetjen L E, Crawford S L, Gajer P, et al. Relationships between the vaginal microbiota and genitourinary syndrome of menopause symptoms in postmenopausal women: the Study of Womens Health Across the Nation［J］. Menopause, 2023, 30(11): 1073－1084.
［47］Micks E, Reed S D, Mitchell C. The postmenopausal vaginal microbiome and genitourinary syndrome of menopause［J］. Clin Obstet Gynecol, 2024, 67(1): 79－88.
［48］Lebeer S, Ahannach S, Gehrmann T, et al. A citizen-science-enabled catalogue of the vaginal microbiome and associated factors［J］. Nat Microbiol, 2023, 8(11): 2183－2195.
［49］de Oliveira N S, de Lima A B F, de Brito J C R, et al. Postmenopausal vaginal microbiome and microbiota［J］. Front Reprod Health, 2021, 3: 780931.
［50］Jongjakapun A, Somboonporn W, Temtanakitpaisan T. Effectiveness of vaginal estriol with lactobacilli on urinary symptoms in postmenopausal women: a randomized-controlled trial［J］. Menopause, 2023, 30(4): 441－446.
［51］Fashemi B E, Wang C H, Chappidi R R, et al. Supraphysiologic vaginal estrogen therapy in aged mice mitigates age-associated bladder inflammatory response to urinary tract infections［J］. Urogynecology, 2023, 29(4): 430－442.
［52］Abou-Taleb H A, Fathalla Z, Naguib D M, et al. Chitosan/solid-lipid nanoparticles hybrid gels for vaginal delivery of estradiol for management of vaginal menopausal symptoms［J］. Pharmaceuticals (Basel), 2023, 16(9): 1284.
［53］Suskind A M, Quanstrom K, Zhao S J, et al. Overactive bladder is strongly associated with frailty in older individuals［J］. Urology, 2017, 106: 26－31.
［54］Cao Y, Zhang H, Tang X H, et al. Alterations in the balance of sex hormones may affect rat prostatic inflammation and fibrosis, and osteopontin might be involved in this process［J］. Int Urol Nephrol, 2023, 55(9): 2355－2365.
［55］Wein A J. Re:overactive bladder is strongly associated with frailty in older individuals［J］. J Urol, 2018, 199(5): 29677910.
［56］Burt E, Davies M C, Yasmin E, et al. Reduced uterine volume after induction of puberty in women with hypogonadism［J］. Clin Endocrinol, 2019, 91(6): 798－804.
［57］Kuno T, Tamura K, Shimizu N, et al. Vibegron 50 mg once daily improves OABSS, OAB-q SF score in OAB patients ≥80 years old in real-world clinical settings and switching from other OAB drugs may reduce residual urine volume［J］. Res Rep Urol, 2023, 15: 157－164.
［58］Shen J W, Luo R, Zhang L, et al. Using electroacupuncture with optimized acupoint positioning to predict the efficacy of sacral neuromodulation of refractory overactive bladder: a case report［J］. Medicine, 2019, 98(45): e17795.
［59］沈建武, 罗然, 孟军, 等. 电针疗法治疗女性膀胱过度活动症的临床研究［J］. 中国中西医结合杂志, 2020, 40(8): 1000－1004.
［60］Zhang P, Zhang Y G, Liao L M, et al. Application of Internet+-based Tsinghua PINS Remote Tech to improve sacral neuromodulation programming procedure［J］. Int Urol Nephrol, 2019, 51(4): 627－632.